Postoperative hyperpyrexia: Retracing malignant hyperthermia

Gupta, Devendra; Ramakant, .; Singh, Prabhat Kumar

doi:10.4103/0970-9185.98370

Cited by 4 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We are reporting this case of possible malignant hyperthermia probably the seventh reported [1][2][3][4][5][6] case in India and second from Kerala in the last decade. This was the first ever case of MH in our institution in 25 years.…”

Section: Introductionmentioning

confidence: 81%

“…We are reporting this case of possible malignant hyperthermia probably the seventh reported case in India and second from Kerala in the last decade (Saxena and Dua, 2007;Punj et al, 2001;Gopalakrishnan et al, 2010;Jain, 2010;Ramakant and Singh, 2012;Sharma et al, 2012). This was the first ever case of MH in our institution in 25 years This emphasises the need to ensure availability of Dantrolene and MH kits, diagnostic centres with appropriate lab controls and above all high index of suspicion and heightened awareness among the anaesthesiologists of this potential albeit rare risk of MH in Indian population.…”

mentioning

confidence: 92%

See 1 more Smart Citation

Malignant hyperthermia in India: Time for awakening, useful facts on Dantrolene

Pillai

Koshy

Balakrishnan

et al. 2015

Egyptian Journal of Anaesthesia

View full text Add to dashboard Cite

A 33 year old lady with no obvious reason to suspect susceptibility to malignant hyperpyrexia (MH) succumbed to this unexpected complication in spite of attempts to save her life with aggressive supportive measures. We are reporting this case of possible malignant hyperthermia probably the seventh reported case in India and second from Kerala in the last decade (Saxena and Dua, 2007;Punj et al., 2001;Gopalakrishnan et al., 2010;Jain, 2010;Ramakant and Singh, 2012;Sharma et al., 2012). This was the first ever case of MH in our institution in 25 years This emphasises the need to ensure availability of Dantrolene and MH kits, diagnostic centres with appropriate lab controls and above all high index of suspicion and heightened awareness among the anaesthesiologists of this potential albeit rare risk of MH in Indian population.

show abstract

Section: Introductionmentioning

confidence: 81%

mentioning

confidence: 92%

Malignant hyperthermia in India: Time for awakening, useful facts on Dantrolene

Pillai

Koshy

Balakrishnan

et al. 2015

Egyptian Journal of Anaesthesia

View full text Add to dashboard Cite

show abstract

“…Similar cases were reported by Gupta et al . [ 12 ] and Pillai et al . [ 13 ] who succumbed in spite of aggressive supportive measures.…”

Section: Discussionmentioning

confidence: 99%

A case report of suspected malignant hyperthermia where patient survived the episode

2017

View full text Add to dashboard Cite

Malignant hyperthermia is rare inherited disorder in our part of the world; there are only few cases reported in literature in India who were suspected of having this condition. The overall incidence of malignant hyperthermia during general anesthesia is estimated to range from 1: 5000 to 1: 50,000–100,000 and mortality rate is estimated to be <5% in the presence of standard care. In India, there is no center where in vitro halothane caffeine contraction test is performed to confirm diagnosis in suspected cases. Second, dantrolene drug of choice for this condition is not freely available in market in India and is stored only in some hospitals in few major cities. Among the cases reported of suspected of malignant hyperthermia in India almost 50% have survived the condition despite nonavailability of dantrolene emphasizing role of early detection and aggressive management in these cases.

show abstract

“…Improved anaesthetic and surgical techniques 14 have contributed to this policy, improving the cost-effectiveness of day-case surgery and limiting escalating healthcare costs. MH reactions in the postoperative period have been well described [15][16][17][18][19] . A review of the suspected cases of postoperative MH in the North American Malignant Hyperthermia Registry from 1987 to 2005 found that, of 528 possible cases, only ten were considered 'likely' MH reactions 18 .…”

Section: Discussionmentioning

confidence: 99%

Safe Duration of Postoperative Monitoring for Malignant Hyperthermia Patients Administered Non-Triggering Anaesthesia: An Update

Barnes

Stowell

Bulger

et al. 2015

Anaesth Intensive Care

View full text Add to dashboard Cite

The postoperative care of malignant hyperthermia (MH) patients is subject to international variation, with a paucity of data in the literature to guide management. Over a series of three studies, our aim was to evaluate whether MH-susceptible patients (and relatives who had not yet been investigated), who had received a non-triggering anaesthetic, could be managed in the same way as the standard surgical population. Following a retrospective study, 206 anaesthetics were administered in a prospective second study to MH-susceptible/related individuals who were monitored for a minimum of one hour in the post anaesthesia care unit and a further 90 minutes in a step-down facility. No problems relating to MH were encountered. The postoperative monitoring time was subsequently changed and, in a third study, patients were managed no differently from standard surgical patients. One hundred and twenty-five anaesthetics were administered with no evidence of problems. This data shows that standard postoperative monitoring times are safe and appropriate in MH-susceptible patients.

show abstract

Postoperative hyperpyrexia: Retracing malignant hyperthermia

Cited by 4 publications

References 5 publications

Malignant hyperthermia in India: Time for awakening, useful facts on Dantrolene

Malignant hyperthermia in India: Time for awakening, useful facts on Dantrolene

A case report of suspected malignant hyperthermia where patient survived the episode

Safe Duration of Postoperative Monitoring for Malignant Hyperthermia Patients Administered Non-Triggering Anaesthesia: An Update

Contact Info

Product

Resources

About